Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

38
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
38
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development and validation of a multiancestry and multitrait polygenic risk score for lung cancer.

Nature communications·2026
Same author

Prediction Pipeline Selection for Incomplete Clinical Data via Missingness Fingerprints and Instance Augmentation.

Bioengineering (Basel, Switzerland)·2026
Same author

Infant-Type Bifidobacteria as Biocontrol Agents: Suppressing <i>Listeria monocytogenes</i> via Key Virulence Gene Alteration.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale·2025
Same author

Boosting the Power of Rare Variant Association Studies by Imputation Using Large-scale Sequencing Population.

Genomics, proteomics & bioinformatics·2025
Same author

Multi-Omics Analysis Revealed Characterization of Gastric Microbiome and Metabolome in Helicobacter pylori-Induced Progression of MASLD.

Helicobacter·2025
Same author

Evaluation of the risk of noise-induced hearing loss and the significance of occupational noise exposure limit among Chinese industrial workers.

The Journal of the Acoustical Society of America·2025

相关实验视频

Updated: Sep 10, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

在2型糖尿病和高血压患者中比较心血管结果和低血糖药物类安全性:多中心队列分析

Zhiyuan Wei1,2, Wanqian Xu3, Yu Wang4

  • 1Department of Medical Informatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.

Cardiovascular diabetology
|August 21, 2025
PubMed
概括

在2型糖尿病和高血压患者中,与胰岛素相比,葡萄糖类-1受体激动剂和二基酶-4抑制剂对心血管有更好的结果. 这些发现为有效管理糖尿病和高血压提供了关键的见解.

关键词:
心血管安全高血压主要心血管不良事件 (MACE)现实世界中的证据追溯研究二型糖尿病

更多相关视频

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

371

相关实验视频

Last Updated: Sep 10, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

371

科学领域:

  • 心脏病学
  • 内分泌学
  • 药理学

背景情况:

  • 患有2型糖尿病 (T2D) 和高血压的患者面临心血管 (CV) 事件的风险增加.
  • 只有有限的实验数据可以比较主要的低血糖药物对心血管的有效性和安全性.

研究的目的:

  • 在T2D高血压患者中直接比较关键低血糖剂的CV结果和安全性.
  • 为优化这一高风险群体的T2D管理提供实践证据.

主要方法:

  • 一个多中心的电子健康记录分析T2D患者的高血压在甲胺.
  • 倾向性得分匹配和考克斯比例危险模型来比较3/4点MACE和添加药物类别 (胰岛素,SU,GLP-1RA,DPP4is,glinides,acarbose,SGLT2is) 的安全结果.

主要成果:

  • 与胰岛素相比,GLP- 1 RAs,DPP4is和glinides的3点MACE风险较低.
  • 与阿卡尔相比,DPP4is,GLP-1RA和glinides的3点MACE风险较低.
  • DPP4与慢性病风险降低,但冠状动脉硬化疾病和高血压心脏病风险增加有关.

结论:

  • 对于高血压T2D患者来说,低血糖疗法在现实环境中具有差异性的心血管疗效和安全性.
  • 这些发现支持选择低血糖药物以改善心血管结果并解决安全问题.